Loading
HKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$8.135
−HK$0.33 · -3.90%
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
Latest quote
HK$8.135
−HK$0.33 · -3.90%
Regular session · HKT · Market data may be delayed.
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
Day range
Current HK$8.135
52-week range
Current HK$8.135
Regular session · HKT · Market data may be delayed.
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
Day range
Current HK$8.135
52-week range
Current HK$8.135
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 13.21B CNY | 13.76B CNY | 13.74B CNY | 11.33B CNY | 9.7B CNY |
| Cost of goods sold | 7.7B CNY | 7.68B CNY | 7.41B CNY | 6.37B CNY | 5.49B CNY |
| Gross profit | 5.51B CNY | 6.08B CNY | 6.33B CNY | 4.97B CNY | 4.21B CNY |
| Research and development | 921.05M CNY | 890.76M CNY | 757.25M CNY | 593.6M CNY | 465.24M CNY |
| Selling, general, and administrative | 2.3B CNY | 2.3B CNY | 2.38B CNY | 2.37B CNY | 2.33B CNY |
| Operating expenses | 3.24B CNY | 3.23B CNY | 3.05B CNY | 2.95B CNY | 2.8B CNY |
| Interest income | 152.57M CNY | 127.79M CNY | 105.42M CNY | 70.74M CNY | 82.78M CNY |
| Interest expense | 69.73M CNY | 34.96M CNY | 66.9M CNY | 81.6M CNY | 60.23M CNY |
| Depreciation and amortization | 613.21M CNY | 538.01M CNY | 565.65M CNY | 523.67M CNY | 596.06M CNY |
| Operating income | 2.27B CNY | 3.12B CNY | 3.29B CNY | 2.02B CNY | 1.41B CNY |
| Net income | 2.09B CNY | 2.66B CNY | 2.7B CNY | 1.58B CNY | 988.1M CNY |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.5693
2025 complete year+292.8% since 2021
2026 partial: HK$0.299
HK$0.1449
2,021
HK$0.1735
2,022
HK$0.3496
2,023
HK$0.6153
2,024
HK$0.5693
2,025
HK$0.299
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 7, 2026 | HK$0.299Annual | Jul 8, 2026 | Jul 22, 2026 |
Dividend | Sep 25, 2025 | HK$0.1751Annual | Sep 26, 2025 | Oct 15, 2025 |
Dividend | Jul 8, 2025 | HK$0.3942Special | Jul 9, 2025 | Jul 23, 2025 |
Dividend | Sep 19, 2024 | HK$0.1763Annual | Sep 20, 2024 | Oct 15, 2024 |
Dividend | Jul 2, 2024 | HK$0.439Special | Jul 3, 2024 | Jul 24, 2024 |
Dividend | Sep 14, 2023 | HK$0.1307Annual | Sep 15, 2023 | Oct 11, 2023 |
Ex-dividend Jul 7, 2026
HK$0.299
Annual
Record Jul 8, 2026 · Payment Jul 22, 2026
Ex-dividend Sep 25, 2025
HK$0.1751
Annual
Record Sep 26, 2025 · Payment Oct 15, 2025
Ex-dividend Jul 8, 2025
HK$0.3942
Special
Record Jul 9, 2025 · Payment Jul 23, 2025
Ex-dividend Sep 19, 2024
HK$0.1763
Annual
Record Sep 20, 2024 · Payment Oct 15, 2024
Ex-dividend Jul 2, 2024
HK$0.439
Special
Record Jul 3, 2024 · Payment Jul 24, 2024
Ex-dividend Sep 14, 2023
HK$0.1307
Annual
Record Sep 15, 2023 · Payment Oct 11, 2023
Funds reporting this stock among their holdings, ordered by reported position size.
Avantis International Small Cap Value ETFAVDV20.91M0.10%20.56B USD0.36%$110.81-0.97%
Vanguard Total International Stock ETFVXUS18.72M0.00%646.2B USD0.05%$86.28-1.29%
Vanguard FTSE Developed Markets ETFVEA12.56M0.00%315B USD0.03%$71.92-1.24%
iShares Core MSCI EAFE ETFIEFA9.64M0.00%196.63B USD0.07%$98.51-0.92%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS5.17M0.04%13.6B USD0.06%$157.42-1.31%
iShares MSCI EAFE Small-Cap ETFSCZ4.08M0.03%13.23B USD0.40%$85.35-0.84%
Schwab International Small-Cap Equity ETFSCHC2.63M0.05%5.77B USD0.06%$50.40-1.49%
Dimensional - International Small Cap ETFDFIS2.47M0.04%5.92B USD0.39%$36.87-0.99%Avantis International Small Cap Value ETFAVDVVanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEAiShares Core MSCI EAFE ETFIEFAVanguard FTSE All-World ex-US Small-Cap ETFVSSiShares MSCI EAFE Small-Cap ETFSCZSchwab International Small-Cap Equity ETFSCHCDimensional - International Small Cap ETFDFISAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
